Paediatric Solid Tumour Biology and Therapeutics Group

Professor Louis Chesler’s group is investigating the genetic causes for the childhood cancers, neuroblastoma, medulloblastoma and rhabdomyosarcoma. 

Research, projects and publications in this group

Our group's aim is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma.

The goal of our laboratory is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma, three paediatric solid tumours in which high-risk patient cohorts can be defined by alterations in a single oncogene. We focus on the role of the MYCN oncogene, since aberrant expression of MYCNis very significantly associated with high-risk in all three diseases and implies that they may have a common cell-of-origin.

Elucidating the molecular signalling pathways that control expression of the MYCN oncoprotein and targeting these pathways with novel therapeutics is a major goal of the laboratory. We use a variety of innovative preclinical drug development platforms for this purpose.

Technologically, we focus on genetically engineered cancer models incorporating novel imaging (optical and fluorescent) modalities that can be used as markers to monitor disease progression and therapeutic response.

Our group has several key objectives:

  • Mechanistically dissect the role of the MYCN oncogene, and other key oncogenic driver genes in poor-outcome paediatric solid tumours (neuroblastoma, medulloblastoma, rhabdomyosarcoma).
  • Develop novel therapeutics targeting MYCN oncoproteins and other key oncogenic drivers
  • Develop improved genetic cancer models dually useful for studies of oncogenesis and preclinical development of novel therapeutics.
  • Use such models to develop and functionally validate optical imaging modalities useful as surrogate markers of tumour progression in paediatric cancer.

Professor Louis Chesler

Clinical Senior Lecturer/Group Leader:

Paediatric Solid Tumour Biology and Therapeutics Professor Louis Chesler (Profile pic)

Professor Louis Chesler is working to understand the biology of children’s cancers and use that information to discover and develop new personalised approaches to cancer treatment. His work focuses on improving the understanding of the role of the MYCN oncogene.

Researchers in this group

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6124

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3617

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4186

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3501

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4361

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6118

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6021

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6196

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6258

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6121

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4527

Email: [email protected]

Location: Sutton

.

OrcID: 0000-0003-3977-7020

Phone: +44 20 3437 6109

Email: [email protected]

Location: Sutton

I obtained an MSci in Biochemistry from the University of Glasgow in 2018. In October 2018 I joined the labs of Dr Michael Hubank and Professor Andrea Sottoriva to investigate the use of liquid biopsy to monitor clonal frequency and emergence of resistance mutations in paediatric cancers.

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6358

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6131

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

Professor Louis Chesler's group have written 113 publications

Most recent new publication 4/2025

See all their publications

Vacancies in this group

Working in this group

Prospect Research Manager

  • Chelsea
  • Development and Communications Directorate
  • £41,600 - £43,000
  • Permanent

About the Role Our Prospect Research team plays a central role in unlocking new funding opportunities across the ICR's philanthropic income streams. It is responsible for delivering high quality, insightful prospect briefings and fundraising intelligence, which supports the ICR's fundraisers in their efforts to build meaningful relationships with philanthropic high net-worth individuals, trusts, foundations and corporates who have the interest and capacity to support the ICR's vital research. The post holder will play a key role in supporting the Development & Communications directorate to source, assess and validate new funding opportunities, maximise income secured across our philanthropic income streams and fundraising campaign, and grow our incredible donor community. The successful candidate will have experience of devising and successfully implementing targeted prospecting strategies. You will play a lead role in identifying philanthropic HNWIs and corporates with the capacity and inclination to support our work. The post holder will also be responsible for carrying out due diligence research and alerting fundraisers to reputational risks identified in support of the ICR's gift acceptance policy. You will work closely with the Head of Prospect Development to support fundraisers in maximising the success of our senior volunteer network through network mapping and expanding its ranks. In addition, the post holder will manage the Prospect Research Executive, providing development and mentoring support. What We Offer A supportive and collaborative working environment. Opportunities for professional development and career progression. Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Caroline Porter via telephone on 020 7153 5486 or email at [email protected].

Higher Scientific Officer (bioinformatician)

  • Sutton
  • Systems and Precision Cancer Medicine
  • £39,805 - £49,023 per annum
  • Fixed term

Under the guidance of Prof Anguraj Sadanandam, we are seeking to recruit a Bioinformatician (Senior Scientific Officer) to contribute to implementing and performing relevant analyses, interpreting the results in context of fast-moving projects, and presenting the results to project teams as well as internal and external collaborators and contribute, with the expectation of authorship on resulting publications. There will also be opportunities to engage in bench-based experimental research, although this is not mandatory. The successful candidate will play a key role in analysing RNAseq data (bulk, single-cell, spatial), developing methodologies and supporting research activities. About you The successful candidate must have: Master’s degree in Computational Biology, Bioinformatics, Computer Science, or related subject Proven experience of bioinformatics analyses and interpretation in one or more of the following key areas (NGS analysis of WES/WGS/RNAseq (bulk, single-cell) using standard practice pipelines; Clinical data analysis (Survival curves, correlation and subgroup analysis) Proven experience in the development of software pipelines to implement analysis workflow Proven experience in use of High Performance Computing platforms and unix-like operating systems Proven experience of writing and maintaining Python, R and Bash code using Git Department/Directorate Information The Division of Molecular Pathology conducts translational research linking molecular science to clinical oncology. The group of Dr Anguraj Sadanandam focuses on cancer metabolism and tumour subtypes, particularly in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). Using integrative multi-omics approaches — including scRNAseq, spatial transcriptomics, bulk RNAseq, metabolomics (LC-MS), CNV, and WES — combined with cell culture and genetically engineered mouse models, we aim to define tumour heterogeneity and identify new therapeutic opportunities. The successful candidate will work under multidisciplinary supervision: for clinical and biological questions, guidance will be provided by Dr Christophe Cisarovsky, Clinical Oncologist in the GI clinic at The Royal Marsden Hospital and MD-PhD, together with Group Leader Prof Anguraj Sadanandam; for technical and bioinformatics questions, supervision will be provided by Prof Anguraj Sadanandam and members of his bioinformatics team. The candidate will primarily perform bioinformatic analyses and contribute to fast-moving projects with the expectation of authorship on resulting publications. There will also be opportunities to engage in bench-based experimental research, although this is not mandatory. https://www.icr.ac.uk/research-and-discoveries/find-a-researcher/test-researcher-profile-detail/dr-anguraj-sadanandam What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Christophe Cisarovsky via Email on [email protected].

Industrial partnership opportunities with this group

Opportunity: A novel test for predicting future cancer risk in patients with inflammatory bowel disease

Commissioner: Professor Trevor Graham

Recent discoveries from this group

06/09/25

The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have teamed up with Sir Chris Hoy and PureGym to launch a collaboration to encourage men with prostate cancer to be more active.

The partnership was launched today, at a PureGym in Glasgow, by six-time Olympic gold medallist Sir Chris Hoy,  PureGym CEO Clive Chesser, and Professor Nick James of the Institute of Cancer Research (ICR) ahead of Sir Chris’s Tour De 4 charity bike ride.

It will see experts at The ICR and The Royal Marsden provide a structured exercise programme, including a free one-year membership at PureGym, for men with advanced prostate cancer on hormone therapy.

Advanced prostate cancer affects around 20,000 men in the UK each year. The main treatment is hormone therapy – side effects include weight gain driven by increase in body fat and muscle loss, fatigue and psychological changes. Long term, these treatments increase the risk of bone thinning, heart disease and diabetes.

Are you on hormone therapy as part of your prostate cancer treatment? You could be suitable for a free PureGym membership and a structured exercise programme.

Register your interest

Exercise can improve quality of life

Research has shown that exercise can result in a better quality of life for men on hormone therapy, with less fatigue, lower body fat and higher muscle mass, and improved bone density. NHS guidelines recommend that men with advanced prostate cancer are offered exercise programmes.

However, few programmes are available, and figures show that around a third of men with advanced prostate cancer are completely inactive and only around one in eight meet guideline levels of activity.

Understanding barriers to exercise

Financial pressures, fatigue, coping with a major illness, and lack of knowledge about how to begin exercising safely, are all recognised as major barriers stopping men with prostate cancer from exercising. This initiative aims to address this.

Professor Nick James, Professor of Prostate and Bladder Cancer Research at The Institute of Cancer Research, London, and Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust. He says:

“A diagnosis of advanced cancer is devastating. I frequently hear patients being advised by their families that they must take it easy and not overexert themselves whereas in most cases, this advice, while well-meaning is not usually true. In fact, the opposite is true.

“There is growing evidence that exercise, as well as improving general well-being, might also directly improve cancer outcomes. Some studies have shown that exercising is so effective that if it was a drug, we would call it a ‘breakthrough’. However, while prostate cancer patients may be advised about the importance of exercise, they are rarely supported to actually begin – or simply continue – exercising safely.

“Joining a gym, particularly when you are older and recently diagnosed with a major illness, is clearly a major psychological hurdle. It’s also a financial barrier for many people, so we’re delighted to partner with PureGym to offer men with locally advanced or metastatic prostate cancer who are on hormone therapy this free access to gym facilities. Alongside this, we will provide a structured exercise programme, which can be undertaken at home or in the gym, with the aim of supporting men to build a regular exercise habit that could improve their quality of life and overall health.”

Sir Chris Hoy says:

“This is a groundbreaking partnership and initiative which demonstrates the power of the Tour De 4, what it can achieve and the legacy it will leave.

“Scientific studies have shown that structured exercise is the perfect complement to many cancer treatments, but we need to break down the barriers that often prevent patients getting consistent and regular physical activity to experience these benefits.

“Exercise has been a fundamental part of my life and never more so than since my diagnosis of prostate cancer. I find it hugely encouraging that the importance of exercise for prostate cancer is being recognised. This is a significant step forward and potentially transformative.

“I have a long-standing association with PureGym which, more than any fitness organisation in the UK, has the scale, reach and capability to make a demonstrable national impact. I look forward to seeing the results of this initiative in the coming months and years.”

Clive Chesser CEO of PureGym says:

“Prostate cancer, the most common cancer among men, is a terrible disease with nearly 50k diagnosed with it each year. For a number of reasons many of these men are not as active as they could be and we want this to change, which is why I am delighted to be announcing this partnership, enabled by our national reach and scale as the UK’s largest gym company. We hope that offering free membership to advanced prostate cancer sufferers will enable thousands, across the country, to benefit from regular exercise with expert guidance from The Institute of Cancer Research and The Royal Marsden.

“As Sir Chris Hoy, with whom we have a long association, has so bravely shown staying active is a great way of managing the disease both mentally and physically and we are proud to be supporting him with his vital mission.”

The initiative

Men with locally advanced or metastatic prostate cancer, on hormone therapy, will be eligible for:

  • Free one-year PureGym membership
  • 26-week exercise programme with videos that can be followed either at home or in the gym, alongside information and resources to support you in your treatment journey.

The exercise programme has been specifically designed for men with prostate cancer that has spread beyond the prostate into the surrounding tissues or has spread to more distant parts of the body. The programme considers fatigue, lower bone density, and risks associated with having prostate cancer that has spread to the bones.

To register your interest in taking part, and for more information, visit icr.ac.uk/puregym